INSIDER
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProMethodologyMatch reviewLaunch readiness
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProMethodologyMatch reviewLaunch readiness
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 430m ago
HOUSE PTR30m ago
SEC 13F30m ago
ROBINHOOD CHAIN29m ago
Public company

HUMAHumacyte, Inc.

CIK 0001818382

EDGAR filingsOpen in network
Disclosed transactions3
Buys / sells0 / 2
Max Insider Score14
Connections5with evidence

HUMA · disclosed activity on price

Disclosed transactions

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
9
KB
Kuznik Paul BrianDirector
HUMAHumacyte, Inc.
Grant or award
A—
125.0K sh
Oct 6, 2026Oct 7, 2026
traded Oct 6, 2026
+1dSEC FORM 4

Evidence

Verified connections

  • In industryevidence
    Pharmaceuticals, devices & health servicesSEC SIC 2836 · Biological Products, (No Diagnostic Substances) · Nov 4, 2026
  • ← Insider ofevidence
    Kuznik Paul BrianDirector · Oct 7, 2026
  • ← Lobbied forevidence
    CAPITOL HILL CONSULTING GROUPLDA Q2 2026 second quarter · Medicare/Medicaid, Health issues, Defense · Aug 26, 2026
  • ← Insider ofevidence
    Parikh Shamik JChief Medical Officer · May 20, 2026
14
PJ
Parikh Shamik JChief Medical Officer
HUMAHumacyte, Inc.
Open-market sale · 10b5-1 plan
SELL
$41K
45.9K sh
May 18, 2026
May 20, 2026
traded May 18, 2026
+2d
SEC FORM 4

Evidence

14
SA
Sander Dale A.CFO and Chief Corp. Dev. Off
HUMAHumacyte, Inc.
Open-market sale · 10b5-1 plan
SELL$41K
45.9K sh
May 18, 2026May 20, 2026
traded May 18, 2026
+2dSEC FORM 4

Evidence

  • ← Insider ofevidence
    Sander Dale A.CFO and Chief Corp. Dev. Off · May 20, 2026

    • Lobbying

    $100K reported · de-duplicated
    2026 Q2 $50K via firms2026 Q1 $50K via firms
    • CAPITOL HILL CONSULTING GROUP$50K2026 Q1 · posted Aug 26, 2026 · Medicare/Medicaid, Health issues, Defense
    • CAPITOL HILL CONSULTING GROUP$50K2026 Q2 · posted Aug 26, 2026 · Medicare/Medicaid, Health issues, Defense

    Connected PAC contributions

    FEC · direct to members

    No contributions from a PAC connected to this company.